Based on preclinical and clinical evidence of an antifibrotic mechanism, two Phase 3 randomized trials of treprostinil as inhaled prescription therapy were conducted for treatment of idiopathic pulmonary fibrosis (IPF). The publication reports the results of the double-blind TETON 1 trial, in which patients with IPF were randomly assigned the inhalation of the experimental drug…
The PHINDER trial is a real-time, collaborative study across many medical centers to improve non-invasive methods of screening for pulmonary hypertension, or PH (dangerously high blood pressure in the lungs), that affects patients with chronic lung scarring disease. The preliminary analysis took data from an initial group of 190 enrolled patients with interstitial lung disease,…
Real-world studies have reported reduced mortality in patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotic therapy; however, the initiation or discontinuation of therapy during these studies may have introduced bias. This study investigated the effect of antifibrotic therapy on mortality and other outcomes in patients with IPF using causal inference methodology.
Dr. Murali Ramaswamy and the team from Pulmonix Research, along with Drs. Martin Portillo of Cone Health Medical Group and Praveen Mannam of LeBauer Pulmonary joined patients and others for a selfie at the Greene Street parking deck in Greensboro. The parking deck was lit in blue marking Pulmonary Fibrosis Awareness Month. Cone Health is part…